Expression of a novel double-mutant dihydrofolate reductase-cytidine deaminase fusion gene confers resistance to both methotrexate and cytosine arabinoside

Human Gene Therapy

Volumn 10, Issue 15, 1999, Pages 2495-2504

  Sauerbrey, Axel ^a,b   McPherson, J Peter ^a   Zhao, Shi Cheng ^a   Banerjee, Debabrata ^a   Bertino, Joseph R ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; CYTIDINE DEAMINASE; DIHYDROFOLATE REDUCTASE; METHOTREXATE; VIRUS VECTOR;

ANIMAL CELL; ARTICLE; BONE MARROW TRANSPLANTATION; CELL PROTECTION; COLONY FORMATION; COLONY FORMING UNIT GM; DRUG EFFECT; ENZYME ACTIVITY; FUSION GENE; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; NONHUMAN; OPEN READING FRAME;

3T3 CELLS; ANIMALS; ARTIFICIAL GENE FUSION; BASE SEQUENCE; BONE MARROW; CELL SURVIVAL; CYTARABINE; CYTIDINE DEAMINASE; DNA PRIMERS; DRUG RESISTANCE; GENETIC VECTORS; KINETICS; METHOTREXATE; MICE; POLYMERASE CHAIN REACTION; RETROVIRIDAE; TETRAHYDROFOLATE DEHYDROGENASE;

ANIMALIA; ARA; FELIS CATUS; UNIDENTIFIED RETROVIRUS;

EID: 0033544031     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430349950016834     Document Type: Article

References (27)

1. AUSUBEL, F.M., BRENT, R., and KINGSTON, R.E. (1987). Current Protocols in Molecular Biology. (John Wiley & Sons, New York).
2. ARAN, J.M., GOTTESMAN, M.M., and PASTAN, I. (1998). Construction and characterization of bicistronic retroviral vectors encoding the multidrug transporter and β-galactosidase or green fluorescent protein. Cancer Gene Ther. 5, 195.
3. BANERJEE, D., SCHWEITZER, B.I., VOLKENANDT, M., LI, M.X., WALTHAM, M., MINEISHI, S., ZHAO, S.C., and BERTINO, J.R. (1994). Transfection with cDNA encoding a Ser 31 or Ser 34 mutant human DHFR into CHO and mouse marrow progenitor cells confers MTX resistance. Gene 139, 269.
4. BERD, D., CORNOG, J., DECONTI, R.C., LEVITT, M., and BERTINO, J.R. (1975). Long term remission in diffuse histiocytic lymphoma treated with combination sequential chemotherapy. Cancer 35, 1050.
5. BRADFORD, M.M. (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding. Anal. Biochem. 72, 248.
6. COREY, C.A., DESILVA, A.D., HOLLAND, C.A., and WILLIAMS, D.A. (1990). Serial transplantation of methotrexate-resistant bone marrow: Protection of murine recipients from drug toxicity by progeny of transduced cells. Blood 75, 337.
7. ERCIKAN-ABALI, E., MINEISHI, S., TONG, Y., NAKAHARA, S., WALTHAM, M.C., BANERJEE, D., CHEN, W., SADELAIN, M., and BERTINO, J.R. (1996a). Active site-directed double mutants of dihydrofolate reductase. Cancer Res. 56, 4142.
8. ERCIKAN-ABALI, E.A., WALTHAM, M.C., DICKER, A.P., SCHWEITZER, B.I., GRITSMAN, H., BANERJEE, D., and BERTINO, J.R. (1996b). Variants of human dihydrofolate reductase with substitutions at leucine 22: Effect on catalytic and inhibitor binding properties. Mol. Pharmacol. 49, 430.
9. FANTZ, C.R., SHAW, D., MORRE, J.G., and SPENCER, H.T. (1998). Retroviral coexpression of thymidylate synthase and dihydrofolate reductase confers fluoropyrimidine and antifolate resistance. Biochem. Biophys. Res. Commun. 243, 6.
10. FREBOURG, T., SADELAIN, M., NG, Y.S., KASSEL, J., and FRIEND, S.H. (1994). Equal transcription of wild type and mutant p53 using bicistronic vectors results in the wild-type phenotype. Cancer Res. 54, 878.
11. INSELBURG, J., and ZHANG, R.D. (1988). Study of dihydrofolate reductase-thymidylate synthase in Plasmodium falciparum. Am. J. Trop. Med. Hyg. 39, 328.
12. LALIBERTE, J., and MOMPARLER, R.L. (1994). Human cytidine deaminase: Purification of enzyme, cloning, and expression of its complementary DNA. Cancer Res. 54, 5401.
13. LALIBERTE, J., MARQUEZ, V.E., and MOMPARLER, R.L. (1992). Potent inhibitors for the deamination of cytosine arabinoside and 5-aza-2′deoxycytidine by human cytidine deaminase. Cancer Chemother. Pharmacol. 30, 7.
14. LEWIS, W.S., CODY, V., GALITSKY, N., LUFT, J.R., PANGBORN, W., CHUNDURU, S.K., SPENCER, H.T., APPLEMAN, J.R., and BLAKELEY, R.L. (1995). Methotrexate-resistant variants of human dihydrofolate reductase with substitution of leucine 22. J. Biol. Chem. 270, 5057.
15. LI, M.-X., BANERJEE, D., ZHAO, S.-C., SCHWEITZER, B.I., MINEISHI, S., GILBOA, E., and BERTINO, J.R. (1994). Development of a retroviral construct containing a human mutated dihydrofolate reductase cDNA for hematopoietic stem cell transduction. Blood 83, 3403.
16. MAREYA, S.M., SORRENTINO, B.P., and BLAKLEY, R.L. (1998). Protection of CCRF-CEM human lymphoid cells from antifolates by retroviral gene transfer of variants of murine dihydrofolate reductase. Cancer Gene Ther. 5, 225.
17. MARKOWITZ, D., GOFF, S., and BANK, A. (1988). Construction and use of a safe and efficient amphotropic packaging cell line. Virology 167, 400.
18. MAY, C., GUNTHER, R., and MCIVOR, R.S. (1995). Protection of mice from lethal doses of methotrexate by transplantation with transgenic marrow expressing drug-resistant dihydrofolate reductase activity. Blood 86, 2439.
19. MOMPARLER, R.L., ELIOPOULOS, N., BOVENZI, V., LETOURNEAU, S., GREENBAUM, M., COURNOYER, D. (1996). Resistance to cytosine arabinoside by retrovirally mediated gene transfer of human cytidine deaminase into murine fibroblasts and hematopoietic cells. Cancer Gene Ther. 3, 331.
20. NEFF, T., and BLAU, A. (1996). Forced expression of cytidine deaminase confers resistance to cytosine arabinoside and gemcitabine. Exp. Hematol. 24, 1340.
21. RIVIERE, I., BROSE, K., and MULLIGAN, R.C. (1995). Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells. Proc. Natl. Acad. Sci. U.S.A. 92, 6733.
22. SCHRODER, J.K., KIRCH, C., FLASSHOVE, M., KALWEIT, H., SEIDELMANN, M., HILGER, R., SEEBER, S., and SCHUTTE, J. (1996). Constitutive expression of the cytidine deaminase gene confers resistance to cytosine arabinoside in vitro. Leukemia 10, 1919.
23. SCHWEITZER, B.I., SRIMATKANDADA, S., GRITSMAN, H., SHERIDAN, R., VENKATARAGHAVAN, R., and BERTINO, J.R. (1989). Probing the role of two hydrophobic active site residues in the human dihydrofolate reductase by site-directed mutagenesis. J. Biol. Chem. 264, 20786.
24. SORRENTINO, B.P., BRANDT, S.J., and BODINE, D. (1992). Selection of drug resistant bone marrow cells in vivo after retroviral transfer of human MDR-1. Science 257, 99.
25. SPENCER, H.T., SLEEP, S.E., REHG, J.E., BLAKLEY, R.L., and SORRENTINO, B.P. (1996). A gene transfer strategy for making bone marrow cells resistant to trimetrexate. Blood 87, 2579.
26. SUGIMOTO, Y., AKSENTIJEVICH, X, MURRAY, G.J., BRADY, R.O., PASTAN, I., and GOTTESMAN, M.M. (1995). Retroviral co-expression of a multidrug resistance gene (MDR1) and human alpha-galactosidase A for gene therapy of Fabry disease. Hum. Gene Ther. 6, 905.
27. ZHAO, S.-C., BANERJEE, D., MINEISHI, S., and BERTINO, J.R. (1997). Post-transplant methotrexate administration leads to improved curability of mice bearing a mammary tumor transplanted with marrow transduced with a mutant human dihydrofolate reductase cDNA. Hum. Gene Ther. 8, 903.